The impact of the centralized volume-based procurement policy on Chinese pharmaceutical manufacturing firms' R&D investment: A difference-in-differences approach.
Centralized drug procurement is a common practice worldwide to relieve the healthcare burden and promote high-quality development in the pharmaceutical industry. However, scholars have not yet reached an agreement on whether centralized procurement can facilitate the innovation activities of pharmac...
Saved in:
| Main Authors: | Fangjun Qiu, Shouming Chen, Yujia Li, Xianjing Wang, Mengfei Zhu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0315811 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Insights from a qualitative study of the procurement and manufacture of active pharmaceutical ingredients in India
by: Heather Hamill, et al.
Published: (2021-09-01) -
Quantum game strategy solution for R&D cartel: Reorganizing government R&D investment strategy in Korea.
by: Dongkyu Won, et al.
Published: (2024-01-01) -
Compliance of Pharmaceutical Manufacturing Companies to Good Manufacturing Practices in Heating, Ventilation, and Air-Conditioning Systems: The Case of Local Ethiopian Firms
by: Desta Tune Tibesso, et al.
Published: (2024-01-01) -
Controlling shareholders’ equity pledge and corporate innovation investment—empirical analysis based on pharmaceutical manufacturing
by: Jiawen Li, et al.
Published: (2025-01-01) -
Research and development investment of Chinese chemical pharmaceutical companies under the national pooled procurement: a retrospective panel data analysis, 2013–2022
by: Yuanli Liu, et al.
Published: (2024-11-01)